Additive Formula 3
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Additive Formula 3
- Generic name
- DEXTROSE MONOHYDRATE, TRISODIUM CITRATE DIHYDRATE, SODIUM CHLORIDE, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, CITRIC ACID MONOHYDRATE, AND ADENINE
- Manufacturer
- Terumo BCT, Ltd
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 9a5247a1-cc05-442d-b2d0-950f887f03c2
- SPL ID
- a93abdba-f409-4b1b-b0d7-ece2189573d9
- Version
- 3
- Effective date
- 2026-01-30
- Source export date
- 2026-09-28
- Source partition
- 8
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/ae3816359e336a5de4f44607730a3d12ceb61ffa012a132189ceda22541b38ee/drug-label-0008-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:56:32
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application number | BN001214 | openfda.application_number | |
| brand name | Additive Formula 3 | openfda.brand_name | |
| generic name | DEXTROSE MONOHYDRATE, TRISODIUM CITRATE DIHYDRATE, SODIUM CHLORIDE, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, CITRIC ACID MONOHYDRATE, AND ADENINE | openfda.generic_name | |
| manufacturer name | Terumo BCT, Ltd | openfda.manufacturer_name | |
| ndc | package | 14537-833-00 | openfda.package_ndc |
| ndc | package | 14537-834-03 | openfda.package_ndc |
| ndc | package | 14537-832-01 | openfda.package_ndc |
| ndc | package | 14537-834-00 | openfda.package_ndc |
| ndc | package | 14537-832-00 | openfda.package_ndc |
| ndc | package | 14537-832-03 | openfda.package_ndc |
| ndc | package | 14537-833-03 | openfda.package_ndc |
| ndc | product | 14537-833 | openfda.product_ndc |
| ndc | product | 14537-834 | openfda.product_ndc |
| ndc | product | 14537-832 | openfda.product_ndc |
| ndc11 | package | 14537083300 | derived:openfda.package_ndc |
| ndc11 | package | 14537083200 | derived:openfda.package_ndc |
| ndc11 | package | 14537083400 | derived:openfda.package_ndc |
| ndc11 | package | 14537083201 | derived:openfda.package_ndc |
| ndc11 | package | 14537083403 | derived:openfda.package_ndc |
| ndc11 | package | 14537083203 | derived:openfda.package_ndc |
| ndc11 | package | 14537083303 | derived:openfda.package_ndc |
| spl id | a93abdba-f409-4b1b-b0d7-ece2189573d9 | id | |
| spl set id | 9a5247a1-cc05-442d-b2d0-950f887f03c2 | set_id | |
| unii | JAC85A2161 | openfda.unii | |
| unii | 2968PHW8QP | openfda.unii | |
| unii | 451W47IQ8X | openfda.unii | |
| unii | B22547B95K | openfda.unii | |
| unii | LX22YL083G | openfda.unii | |
| unii | 593YOG76RN | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Verify that the AS-3 bag has been securely attached to the system tubing set. Use aseptic technique throughout all procedures to ensure product quality. Do not reuse. Discard unused or partially used solution bags. Verify that the AS-3 bag has been securely attached to the system tubing set. Use aseptic technique throughout all procedures to ensure product quality. ( 5 ) Do not reuse. Discard unused or partially used solution bags.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS Citrate reactions or toxicity may occur with the infusion of blood products to patients. The recipient of the blood containing citrate should be monitored for the signs and symptoms of citrate toxicity. The signs and symptoms of citrate toxicity begin with paresthesia, a "tingling" sensation around the mouth or in the extremities, followed by severe reactions that are characterized by hypotension and possible cardiac arrhythmia. Citrate toxicity may occur more frequently in patients who are hypothermic, have impaired liver or renal function, or have low calcium levels because of an underlying disease. Citrate reactions or toxicity may occur with the infusion of blood containing citrate. The recipient of the blood containing citrate should be monitored for the signs and symptoms of citrate toxicity. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Terumo BCT, Inc. at 1-877-339-4228 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.